Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis

作者
Lawrence F. Eichenfield,Vincent Ho,Janice MATSUNAGA,Patricia Leclerc,Carle F. Paul,Jon M. Hanifin
出处
期刊:Journal of Dermatology [Wiley]
卷期号:34 (4): 231-236 被引量:22
标识
DOI:10.1111/j.1346-8138.2007.00259.x
摘要

Pimecrolimus cream 1% is a topical calcineurin inhibitor for the treatment of atopic dermatitis. Minimal systemic exposure to pimecrolimus has been previously observed in Caucasian pediatric patients treated with the cream twice daily for up to 1 year. The objective of this open-label, non-comparative, multicenter study was to assess the systemic exposure, tolerability and efficacy of pimecrolimus cream 1% when used twice daily for 3 weeks in pediatric patients of Japanese background. The patient cohort consisted of 17 Japanese infants and children (age range, 3.6 months to 11.6 years) with atopic dermatitis of at least mild severity affecting >or=10% of the total body surface area (range, 10-48%). Pimecrolimus cream 1% was applied twice daily for 3 weeks. Blood levels of pimecrolimus were determined on days 1, 10 and 22. Safety and tolerability were evaluated by monitoring adverse events, laboratory parameters, physical condition and vital signs. Efficacy parameters included the Eczema Area and Severity Index, the Investigators' Global Assessment and the pruritus score. The median exposure to pimecrolimus cream 1% was 22 treatment days (range, 9-29 treatment days). Pimecrolimus blood concentrations were <0.5 ng/mL in 94% of samples on day 1, in 93% of samples on day 10 and in 100% of samples on day 22, with no indication of an increase with increasing body surface area treated (up to 48% of the total body surface area). No drug-related systemic adverse events or serious adverse events were reported. Treatment was effective according to all efficacy parameters. The findings of this study indicate that the use of pimecrolimus cream 1% results in minimal systemic absorption of the active ingredient in pediatric patients of Japanese background with extensive disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.3的应助被wang采纳,获得10
1秒前
酷波er的应助被SKHC采纳,获得10
1秒前
东方自远完成签到,获得积分10
1秒前
cyy关注了科研通微信公众号
1秒前
3秒前
华夫饼发布了新的文献求助10
3秒前
星星发布了新的文献求助10
3秒前
4秒前
这题不讲发布了新的文献求助10
5秒前
五号发布了新的文献求助10
5秒前
6秒前
大模型的应助被刘辞忧采纳,获得10
6秒前
Maestro_S的应助被DW采纳,获得50
7秒前
米娅发布了新的文献求助10
8秒前
稻草熊完成签到,获得积分10
8秒前
Jasper的应助被风朝东采纳,获得10
10秒前
10秒前
clp必发sci完成签到 ,获得积分10
11秒前
cdercder的应助被jay采纳,获得10
11秒前
11秒前
可妍昇发布了新的文献求助10
11秒前
lxy完成签到,获得积分20
11秒前
11秒前
12秒前
852的应助被wangfei采纳,获得10
12秒前
斯文败类的应助被123采纳,获得30
12秒前
123xol完成签到,获得积分10
13秒前
超级的夹心饼干完成签到,获得积分10
13秒前
13秒前
15秒前
大气幻柏发布了新的文献求助10
16秒前
SKHC完成签到,获得积分10
16秒前
17秒前
吉伊拯救世界完成签到 ,获得积分10
17秒前
cyy发布了新的文献求助10
17秒前
18秒前
18秒前
fxl完成签到,获得积分10
19秒前
業業发布了新的文献求助10
20秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188249
求助须知:如何正确求助?哪些是违规求助? 9576071
关于积分的说明 21845183
捐赠科研通 7786256
什么是DOI,文献DOI怎么找? 3435261
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482169